Moffitt Cancer Center's Sarcoma Program specializes in the evaluation and treatment of all sarcomas, including gastrointestinal stromal tumors (GIST), retroperitoneal tumors, bone and soft tissue tumors. As a high-volume cancer center with one of the most specialized sarcoma programs in the country, Moffitt is one of the most trusted names for referring physicians nationwide. Our advanced program accepts referrals for both adult and pediatric sarcoma patients, as well as patients who require further diagnostic testing to confirm or rule out a sarcoma diagnosis.
With a single referral, physicians can arrange for their patients to consult with several medical professionals in a single clinic. Patients in Moffitt's Sarcoma Program have the ability to consult with:
- Medical oncologists
- Radiation oncologists
- Orthopaedic oncologists - adult and pediatric
- Surgical oncologists
- Reconstructive surgeons
- Specialized radiologists
- Nutritionists and other supportive care providers
This multispecialty team of experts collaboratively assesses each patient's case to determine the most promising therapies and integrative treatments. We discuss cases during weekly multidisciplinary sarcoma-specific tumor board.
Our treatment plans are tailored to each patient case and include all of the latest advancements in standard of care sarcoma treatment, such as immunotherapy, molecular targeted therapeutics, complex reconstruction surgeries, noninvasive expandable pediatric limb endoprosthesis, computer navigation and limb salvage surgeries. We also offer a full array of experimental therapy through our robust clinical trial program which gives patients the opportunity to access innovative therapies such as oncolytic virus therapy, autologous cellular immunotherapy and gene-modified T-cell therapy, where our program leads the frontier of therapy to establish new standards in care for all sarcoma patients.
Our sarcoma medical oncologists were involved in the development of a new clinical program, Immune Cell Therapy (ICE-T) Medical Service. The ICE-T medical service was developed to gain expertise caring for patients treated with TCR and CAR T cells, or other immunotherapies with high risk for acute toxicities including Tumor Infiltrating Lymphocyte (TIL) therapy. Through this collaboration, our sarcoma medical oncologists gained experience with cytokine release syndrome and neurological toxicities caused by CARs, TCRs and TILs.
As part of the ICE-T service, our sarcoma medical oncologists are rounding on the inpatient and outpatient service taking care of the patients treated with the commercial CAR-T, as well all the high-risk immunotherapy trials involving CAR-T, TCR and other immunotherapeutic strategies.
Call toll-free 1-800-679-0775 or locally 813-745-6100 to speak with a Clinical Trial Navigator about clinical trials that match your patient’s diagnosis and treatment history.
To refer a patient to Moffitt's Sarcoma Program, complete our online form or contact a physician liaison for assistance or support. To keep referral times as short as possible, we respond to virtually all online referrals on the same day on which they are received.
Medically reviewed by Odion Binitie, MD and John Mullinax, MD, Sarcoma Program